On-demand treatment

People with von Willebrand disease may require on-demand treatment for bleeding, including nosebleeds, prolonged bleeding from minor cuts, bleeding during dental treatment, and heavy menstrual bleeding.1


The efficacy of wilate® for on-demand treatment of bleeds has been demonstrated in clinical trials in adults and children with all von Willebrand disease types and is supported by data from real-world studies.2, 5

Need for effective on-demand treatment

in von Willebrand disease6, 7

People with von Willebrand disease can be susceptible to spontaneous and traumatic bleeding, including

The efficacy of wilate®

for on-demand treatment of bleeds has been demonstrated in clinical trials in adults and children with all types of von Willebrand disease2*

Data from four prospective, Phase II and III trials **

2-2_3@2x

* Indication: Prevention and treatment of haemorrhage or surgical bleeding in von Willebrand disease, when desmopressin treatment alone is ineffective or contra-indicated. 

The efficacy of wilate®

for on-demand treatment of bleeds has been demonstrated in clinical trials in adults and children with all types of von Willebrand disease2

Data from four prospective, Phase II and III trials

2-2_4@2x

wilate® efficacy rated ‘excellent’ or ‘good’

of 1095 treated bleeding events

The efficacy of wilate®

for on-demand treatment of bleeds has been demonstrated in clinical trials in adults and children with all types of von Willebrand disease2

Data from four prospective, Phase II and III trials

2-2_5@2x

The efficacy of wilate®

for on-demand treatment of bleeds is supported by data from real-world studies

WIL-20: Non-interventional Phase IV study3

WIL-20 included 111 patients (aged 1 to 83 years) at 31 centres. 29 patients were treated on-demand with wilate®

2-2_6@2x

wilate® efficacy rated ‘excellent’ or ‘good’ in

of 127 treated bleeding events in 25 patients*

*as rated by the investigator.

The efficacy of wilate®

for on-demand treatment of bleeds is supported by data from real-world studies

Real-world retrospective studies

wilate® efficacy rated ‘excellent’ or ‘good’ in

25 adults
(median age 42 years, range 19–82 years)4

of 46 bleeding events

15 adolescents and children (median age 7 years, range 0–17 years)5

of 44 bleeding events

References

  1. de Wee EM et al. Thromb Haemost 2012; 108:683-92.
  2. Berntorp E et al. Haemophilia 2009; 15:122-30.
  3. Sholzberg M et al. TH Open 2021; 5:e264-72.
  4. Batty P et al. Haemophilia 2014; 20:846-53.
  5. Khair K et al. Haemophilia 2015; 21:e44-50.
  6. Lillicrap D and James P. WFH Treatment of Hemophilia 2009; No. 47 (available at https://www1.wfh.org/publication/files/pdf-1204.pdf).
  7. Castaman G et al. Haematologica 2013; 98:667-74.